New analysis of the current clinical trial landscape in the UK shows clear opportunities to shape the future of medical research and patient care. The ...

The MHRA has approved trofolastat to identify how far high-risk prostate cancer has spread before treatment, to detect ...

The World Health Organization (WHO) has confirmed the successful redesignation of the Medicines and Healthcare products ...

The MHRA has approved eplontersen (Wainzua) for treating adults with polyneuropathy associated with hereditary transthyretin ...

Trofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion ...

The MHRA has introduced seven new CERSIs to modernise healthcare regulation and accelerate patient access to innovative ...

UK MHRA approves eplontersen to treat adults with rare inherited nerve disease or polyneuropathy: United Kingdom Monday, April 7, 2025, 15:00 Hrs [IST] The Medicines and Healthcar ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

4basebio PLC has been granted Good Manufacturing Practice (GMP) certification by the UK’s Medicines and Healthcare products ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new monthly safety bulletins aimed at making ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...